In spite of plummeting valuation, 23andMe still aims to pivot into biotech
Podcast |
Marketplace Tech
Publisher |
Marketplace
Media Type |
audio
Categories Via RSS |
News
Technology
Publication Date |
Feb 13, 2024
Episode Duration |
00:11:47

23andMe has seen its valuation plummet from $6 billion to close to zero, with the Nasdaq threatening to delist the company’s stock. Still, company leaders have high hopes for medical research and a pivot to biotech. Rolfe Winkler has been writing about what happened for The Wall Street Journal, and discussed the company’s financial woes and future roadmap with Marketplace’s Lily Jamali.

This episode currently has no reviews.

Submit Review
This episode could use a review!

This episode could use a review! Have anything to say about it? Share your thoughts using the button below.

Submit Review